Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

4.970 +0.090 (+1.84%)
Streaming Delayed Price Updated: 3:51 PM EST, Nov 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,079,093
Open 4.910
Bid (Size) 4.960 (34)
Ask (Size) 4.970 (30)
Prev. Close 4.880
Today's Range 4.870 - 5.070
52wk Range 4.490 - 24.45
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga

Performance

YTD
-77.89%
-77.89%
1 Month
-38.87%
-38.87%
3 Month
-33.82%
-33.82%
6 Month
-55.94%
-55.94%
1 Year
-72.90%
-72.90%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Via Benzinga
Why Is Aurinia Pharmaceuticals (AUPH) Stock Down 30%?
Via InvestorPlace
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
Via Benzinga
Recap: Aurinia Pharmaceuticals Q3 Earnings
Via Benzinga
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Earnings Preview For Aurinia Pharmaceuticals
Via Benzinga
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Via Benzinga
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
NASDAQ: AUPH Long Term Investor Alert: Investigation of Potential Wrongdoing at Aurinia Pharmaceuticals Inc.
Via SBWire
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Plunging
Via Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Via Benzinga
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.